Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

Johnson & Johnson maintains a 'Buy' rating, driven by robust Q2 2026 sales growth and pipeline advancements. JNJ's top-performing drugs, DARZALEX and TREMFYA, fueled a 6.6% revenue increase to $25.3 billion, prompting raised full-year 2026 guidance. CAPLYTA's label expansion for schizophrenia relapse prevention and IMAAVY's potential first-mover status in wAIHA represent major growth catalysts. Risks include uncertain sustainability of high sales growth rates and regulatory outcomes for key pipeline assets.

The last time I spoke about Johnson & Johnson (JNJ), it was with a Seeking Alpha article entitled "Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating.